iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/22563139
ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 1;35(8):613-620.

ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease

J A Shayman  1
Affiliations

ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease

J A Shayman. Drugs Future. .

Abstract

Eliglustat tartrate (Genz-112638) is a novel, orally administered agent currently in development for the treatment of lysosomal storage disorders, including type 1 Gaucher disease and Fabry disease. This glucosylceramide analogue acts as an inhibitor of glucosylceramide synthase, a Golgi complex enzyme that catalyzes the formation of glucosylceramide from ceramide and UDP-glucose and is the first step in the formation of glucocerebroside-based glycosphingolipids. Pre-clinical pharmacological studies demonstrate that the agent has a high therapeutic index, excellent oral bioavailability and limited toxicity. Phase I studies in healthy volunteers revealed limited toxicity with an excellent pharmacodynamic response, as measured by decreased plasma glucosylceramide concentrations. Phase II studies in patients with type 1 Gaucher disease have demonstrated promising clinical responses, as measured by decreases in spleen size, improvement in hemoglobin concentrations and increased platelet counts. Two randomized phase III trials testing the efficacy and safety of eliglustat tartrate are currently in progress.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pathways for simple glycosphingolipid synthesis and degradation. In Gaucher disease glucosylceramide accumulates due to a decrease or loss of activity of β-glucocerebrosidase; in Fabry disease globotriaosylceramide accumulates due to a loss or decreased activity of β-galactosidase A. Conventional enzyme replacement therapy directly restores deficient enzyme through i.v. infusion of the respective glycosidase. Eliglustat tartrate blocks the first step in glycosphingolipid synthesis, glucosylceramide synthase. In the presence of eliglustat tartrate, all glucosylceramide-based glycosphingolipids are inhibited, including globotriaosylceramide.
Scheme 1
Scheme 1
Synthesis of Eliglustat
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dellaria JF, Jr, Santarsiero BD. Enantioselective synthesis of alpha-amino acid derivatives via the stereoselective alkylation of a homochiral glycine enolate synthon. J Org Chem. 1989;54(16):3916–26.
    1. Siegel C, Hirth BH Genzyme Corp. CA 2453978, EP 1409467, EP 2067775, JP 2005255686, JP 2005502635, JP 2010095546, US 2003050299, US 6855830, WO 2003008399 Synthesis of UDP-glucose:N-acyl-sphingosine glucosyltransferase inhibitors.
    1. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160(18):2835–43. - PubMed
    1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54. - PubMed
    1. Grabowski GA. Gaucher disease: Gene frequencies and genotype/phenotype correlations. Genet Test. 1997;1(1):5–12. - PubMed

LinkOut - more resources